50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials.
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results